Authors: Goshorn, S Sanderson, J Axworthy, D Lin, YK Hylarides, M Schultz, J

Citation: S. Goshorn et al., Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy, CANC BIO R, 16(2), 2001, pp. 109-123

Authors: Press, OW Corcoran, M Subbiah, K Hamlin, DK Wilbur, DS Johnson, T Theodore, L Yau, E Mallett, R Meyer, DL Axworthy, D

Citation: Ow. Press et al., A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts, BLOOD, 98(8), 2001, pp. 2535-2543

Authors: Weiden, PL Breitz, HB Press, O Appelbaum, JW Bryan, JK Gaffigan, S Stone, D Axworthy, D Fisher, D Reno, J

Citation: Pl. Weiden et al., Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results, CANC BIO R, 15(1), 2000, pp. 15-29

Authors: Knox, SJ Goris, ML Tempero, M Weiden, PL Gentner, L Breitz, H Adams, GP Axworthy, D Gaffigan, S Bryan, K Fisher, DR Colcher, D Horak, ID Weiner, LM

Citation: Sj. Knox et al., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer, CLIN CANC R, 6(2), 2000, pp. 406-414

Authors: Schultz, J Lin, YK Sanderson, J Zuo, YT Stone, D Mallett, R Wilbert, S Axworthy, D

Citation: J. Schultz et al., A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy, CANCER RES, 60(23), 2000, pp. 6663-6669